Determination of clinical phenotypes of chronic obstructive pulmonary disease a new treatment approach


Cite item

Full Text

Abstract

Chronic obstructive pulmonary disease (COPD) is a syndrome including a group of obstructive diseases showing both similar features and marked differencies. At present, clinicians try to describe various COPD phenotypes reflecting different characteristics of the patients which can be useful in respect of COPD course, prognosis and effective treatment. The article is devoted to approaches to COPD phenotypes definition, gives descriptions of some possible phenotypes and analyses clinical trials of modern COPD treatment modalities in different phenotypes.

About the authors

Sergey Nikolaevich Avdeev

S N Avdeev

State Research Institute of Pulmonology, Moscow

State Research Institute of Pulmonology, Moscow

References

  1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/ WHO workshop report. Last updated 2009. www.goldcopd/ org/.
  2. Anthonisen N. R., Wright E. C., Hodgkin J. E. The IPPB Trial Group. Prognosis in chronic obstructive pulmonary disease. Am. Rev. Respir. Dis. 1986; 133: 14-20.
  3. Celli B. R., MacNee W. Standards for the diagnosis and treatment of COPD. Eur. Respir. J. 2004; 23: 932-946.
  4. Agusti A. G. N., Noguera A., Sauleda J. et al. Systemic effects of chronic obstructive pulmonary disease. Eur. Respir. J. 2003; 21: 347-360.
  5. Casanova C., Cote C., de Torres J. P. et al. Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2005; 171: 591-597.
  6. Schols A. M., Slangen J., Volovics L., Wouters E. F. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1998; 157: 1791-1797.
  7. Maltais F., LeBlanc P., Jobin J. et al. Intensity of training and physiologic adaptation in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1997; 155: 555-561.
  8. Nishimura K., Izumi T., Tsukino M., Oga T. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest 2002; 121: 1434-1440.
  9. Reilly J. J. COPD and declining FEV1-time to divide and conquer? N. Engl. J. Med. 2008; 359: 1616-1618.
  10. Burrows B., Fletcher C. M., Heard B. E. et al. The emphysematous and bronchial types of chronic airways obstruction. A clinicopathological study of patients in London and Chicago. Lancet 1966; 87: 830-835.
  11. Garcia-Aymerich J., Agusti A., Barbera J. A. et al. Phenotypic heterogeneity of chronic obstructive pulmonary disease. Arch. Bronchoneumol. 2009; 45: 133-142.
  12. Agusti A., Calverley P. M. A., Celli B. et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir. Res. 2010; 11: 122.
  13. Burgel P. R., Paillasseur J. L., Caillaud D. et al. Clinical COPD phenotypes: a novel approach using principal component and cluster analyses. Eur. Respir. J. 2010; 36: 1-9.
  14. Rice J. P., Saccone N. L., Rasmussen E. Definition of the phenotype. Adv. Genet. 2001; 42: 69-76.
  15. Han M. K., Agusti A., Calverley P. M. et al. COPD phenotypes. The future of COPD. Am. J. Respir. Crit. Care Med. 2010; 182: 598-604.
  16. Dornhorst A. C. Respiratory insufficiency. Lancet 1955; 268: 1185-1187.
  17. Diaz O., Villafranca C., Ghezzo H. et al. Role of inspiratory capacity on exercise tolerance in COPD patients with and without expiratory flow limitation at rest. Eur. Respir. J 2000; 16: 269-275.
  18. Mair G., Miller J. J., McAllister D. et al. Computed tomographic emphysema distribution: relationship to clinical features in a cohort of smokers Eur. Respir. J. 2009; 33: 536- 542.
  19. Gietema H. A., Zanen P.l, Schilham A. et al. Distribution of emphysema in heavy smokers: impact on pulmonary function. Respir. Med. 2010; 104: 76-82.
  20. Dirksen A. Is CT a new research tool for COPD? Clin. Respir. J. 2008; 2: 76-83.
  21. Makita H., Nasuhara Y., Nagai K., Ito Y. Characterisation of phenotypes based on severity of emphysema in chronic obstructive pulmonary disease. Thorax 2007; 62: 932-937.
  22. Fishman A., Martinez F., Naunheim K. et al., and the National Emphysema Treatment Trial Research Group. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N. Engl. J. Med. 2003; 348: 2059-2073
  23. V. Revisited role for mucus hypersecretion in the pathogenesis of COPD. Eur. Respir. Rev. 2010; 19 (116): 109-112.
  24. Vestbo J., Prescott E., Lange P. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am. J. Crit. Care Med. 1996; 153: 1530-1535.
  25. Annesi I., Kauffman F. Is respiratory mucus hypersecretion really an innocent disorder? A 22-year mortality survey of 1,061 working men. Am. Rev. Respir. Dis. 1986; 134: 688-693.
  26. Speizer F. E., Fay M. E., Dockery D. W. et al. Chronic obstructive pulmonary disease mortality in six U. S. cities. Am. Rev. Respir. Dis. 1989; 140 (Suppl. 3): S49-S55.
  27. De Marco R., Accordini S., Cerveri I. et al. Incidence of chronic obstructive pulmonary disease in a cohort of young adults according to the presence of chronic cough and phlegm. Am. J. Respir. Crit. Care Med. 2007; 175: 32-39.
  28. Ulrik C. S. Outcome of asthma: longitudinal changes in lung function. Eur. Respir. J. 1999; 13: 904-918.
  29. Lange P., Parner J., Vestbo J. et al. A 15-year follow-up study of ventilatory function in adults with asthma. N. Engl. J. Med. 1998; 339: 1194-1200.
  30. Ulrik C. S., Backer V. Nonreversible airflow obstruction in life-long nonsmokers with moderate to severe asthma. Eur. Respir. J. 1999; 14: 892-896.
  31. Fabbri L. M., Romagnoli M., Coretta L. et al. Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2003; 167: 418-424.
  32. Schols A. M., Slangen J., Volovics L., Wouters E. F. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1998; 157: 1791-1797.
  33. Landbo C., Prescott E., Lange P. et al. Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1999; 160: 1856-1861.
  34. Di Francia M., Barbier D., Mege J. L., Orehek J. Tumor necrosis factor-alpha levels and weight loss in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1994; 150: 1453-1455.
  35. Saey D., Debigare R., LeBlanc P. et al. Contractile leg fatigue after cycle exercise: a factor limiting exercise in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2003; 168: 425-430.
  36. Decramer M., Gosselink R., Troosters T. et al. Muscle weakness is related to utilization of health care resources in COPD patients. Eur. Respir. J. 1997; 10: 417-423.
  37. Agusti A. G., Sauleda J., Miralles C. et al. Skeletal muscle apoptosis and weight loss in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2002; 166: 485-489.
  38. Soriano J. B., Maier W. C., Egger P. et al. Recent trends in physician diagnosed COPD in women and men in the UK. Thorax 2000; 55: 789-794.
  39. Foy C. G., Rejeski J. Berry M. J. et al. Gender moderates the effects of exercise therapy on health-related quality of life among COPD patients. Chest 2001; 119: 70-76.
  40. Kanner R. E., Connet J. E., Murray D. A. et al. Lung Health Study. Gender difference in airway hyperresponsiveness in smokers with mild COPD. Am. J. Respir. Crit. Care Med. 1994; 150: 956-961.
  41. de Torres J. P., Casanova C., Hernändez C. et al. Gender and chronic obstructive pulmonary disease in patients attending a pulmonary clinic. Chest 2005; 128: 20012-20016.
  42. Seemungal T. A. R., Donaldson G. C., Paul E. A. et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1998; 157: 1418-1422.
  43. Wedzicha J. A., Donaldson G. C. Exacerbations of chronic obstructive pulmonary disease. Respir. Care 2003; 48: 1204- 1213.
  44. Seemungal T. A. R., Donaldson G. C., Bhowmik A. et al. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2000; 161: 1608-1613.
  45. Bhowmik A.l, Seemungal T. A. R., Sapsford R. J., Wedzicha J. A. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax 2000; 55: 114-120.
  46. Groenewegen K. H., Postma D. S., Hop W. C. J. et al. Increased systemic inflammation is a risk factor for COPD exacerbations. Chest 2008; 133: 350-357.
  47. Hurst J. R., Vestbo J., Anzueto A. et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N. Engl. J. Med. 2010; 363: 1128-1138.
  48. Anthonisen N. R., Connett J. E., Kiley J. P. et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilatator on the rate of decline of FEV1. The Lung Health Study. J. A. M. A. 1994; 272: 1497-1505.
  49. Anthonisen N. R., Skeans M. A., Wise R. A. et al. The effects of a smoking cessation intervention on 14,5-year mortality: a randomized clinical trial. Ann. Intern. Med. 2005; 142: 233-239.
  50. de Torres J. P., Cordoba-Lanus E., Lopez-Aguilar C. et al. C-reactive protein levels and clinically important predictive outcomes in stable COPD patients. Eur. Respir. J. 2006; 27: 902-907.
  51. Godtfredsen N. S., Vestbo J., Osler M., Prescott E. Risk of hospital admission for COPD following smoking cessation and reduction: a Danish population study. Thorax 2002; 57: 967- 972.
  52. Sin D. D., Wu L., Anderson J. A. et al. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax 2005; 60: 992-997.
  53. Barnes N. C., Qiu Y. S., Pavord I. D. et al. Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am. J. Respir. Crit. Care Med. 2006; 173: 736-743.
  54. Flenley D. C. Sleep in chronic obstructive lung disease. Clin. Chest Med. 1985; 6: 651-661.
  55. Sanders M. H. The upper airway and sleep-disordered breathing: getting the big picture. Am. J. Respir. Crit. Care Med. 2003; 168: 509-510.
  56. Report of the Medical Research Council Working Party. Long-term domiciliary oxygen therapy in chronic hypoxic or pulmonale complicating chronic bronchitis and emphysema. Lancet 1981; 1: 681-685.
  57. Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease. Ann. Intern. Med. 1980; 93: 391-398.
  58. Burge P. S., Calverley P. M., Jones P. W. et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Br. Med. J. 2000; 320: 1297-1303.
  59. Nishimura K., Izumi T., Tsukino M., Oga T. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest 2002; 121: 1434-1440.
  60. Domingo-Salvany A., Lamarca R., Ferrer M. et al. Health-related quality of life and mortality in male patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2002; 166: 680-685.
  61. Celli B. R., Cote C. G., Marin J. M. et al. The body mass index, airflow obstruction, dyspnea and exercise capacity index in chronic obstructive pulmonary disease. N. Engl. J. Med. 2004; 350: 1005-1012.
  62. Martinez F. J., Han M. K., Andrei A. C. et al. National Emphysema Treatment Trial Research Group. Longitudinal change in the BODE index predicts mortality in severe emphysema. Am. J. Respir. Crit. Care Med. 2008; 178: 491-499.
  63. Soler-Cataluna J. J., Martinez-Garcia M. A., S@anchez L. S. Severe exacerbations and BODE index: two independent risk factors for death in male COPD patients. Respir. Med. 2009; 103: 692-699.
  64. Jones R. C., Donaldson G. C., Chavannes N. H. et al. Derivation and validation of a composite index of severity in chronic obstructive pulmonary disease - the DOSE index. Am. J. Respir. Crit. Care Med. 2009; 180: 1189-1195.
  65. Puhan M. A., Garcia-Aymerich J., Frey M. et al. Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: The updated BODE index and the ADO index. Lancet 2009; 374: 704-711.
  66. Briggs A., Spencer M., Wang H. et al. Development and validation of a prognostic index for health outcomes in chronic obstructive pulmonary disease. Arch. Intern. Med. 2008; 168: 71-79.
  67. Azarisman M. S., Fauzi M. A., Faizal M. P. et al. The SAFE (SGRQ score, air-flow limitation and exercise tolerance) index: A new composite score for the stratification of severity in chronic obstructive pulmonary disease. Postgrad. Med. J. 2007; 83: 492-497.
  68. Lee J.-H., Lee Y. K., Kim E.-K. et al. Responses to inhaled long-acting beta-agonist and corticosteroid according to COPD subtype. Respir. Med. 2010;104: 542-549.
  69. Gelb A. F., Taylor C. F., Cassino C. et al. Tiotropium induced bronchodilation and protection from dynamic hyperinflation is independent of extent of emphysema in COPD. Pulm. Pharmacol. Ther. 2009; 22: 237-242.
  70. Tashkin D. P., Celli B., Senn S. et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N. Engl. J. Med. 2008; 359: 1543-1554.
  71. Troosters T., Celli B., Lystig T. et al. Tiotropium as a first maintenance drug in COPD secondary anaysis of the UPLIFT trial. Eur. Respir. J. 2010; 36: 65-73.
  72. Morice A. H., Celli B., Kesten S. et al. COPD in young patients: A prespecified analysis of the four-year trial of tiotropium (UPLIFT). Respir. Med. 2010; 104: 1659-1667.
  73. Tashkin D. P., Celli B., Kesten S. et al. Long-term efficacy of tiotropium in relation to smoking status in the UPLIFT trial. Eur. Respir. J. 2010' 35: 287-294.
  74. Tashkin D. P., Celli B., Kesten S. et al. Effect of tiotropium in men and women with COPD: Results of the 4-year UPLIFT trial. Respir. Med. 2010; 104: 1495-1504.
  75. Pena V. C., Miravitlles M., Gabriel R. et al. Geographic variations in prevalence and underdiagnosis of COPD: results of the IBERPOC multicentre epidemiological study. Chest 2000; 118: 981-989.
  76. Lopez A. D., Shibuya K., Rao C. et al. Chronic obstructive pulmonary disease: current burden and future projections. Eur. Respir. J. 2006; 27: 397-412.
  77. Жестков А. В., Косарев В. В., Бабанов С. А. Хроническая обструктивная болезнь легких у жителей крупного промышленного центра: эпидемиология и факторы риска. Пульмонология 2009; 6: 53-57.
  78. Mannino D. M., Homa D. M., Akinbami L. J. et al. Chronic obstructive pulmonary disease surveillance - United States, 1971-2000. Morbid. Mortal. Wkly Rep. Surveill. Summ. 2002; 51: 1-16.
  79. Fletcher C., Peto R. The natural history of chronic airflow obstruction. Br. Med. J. 1977; 1: 1645-1648.
  80. Moita J., Barbara C., Cardoso J. et al. Tiotropium improves FEV1 in patients with COPD irrespective of smoking status. Pulm. Pharmacol. Ther. 2008; 21: 146-151.
  81. Rennard S. I., Serby C. W., Ghafouri M. et al. Extended therapy with ipratropium is associated with improved lung function in patients with COPD. Chest 1996; 110: 62-70.
  82. Camp P. G., O'Donnell D. E., Postma D. S. Chronic obstructive pulmonary disease in men and women. Myths and reality. Proc. Am. Thorac. Soc. 2009; 6: 535-538.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2011 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies